Edition:
United Kingdom

Nymox Pharmaceutical Corp (NYMX.OQ)

NYMX.OQ on NASDAQ Stock Exchange Capital Market

3.13USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$3.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,992
52-wk High
$5.10
52-wk Low
$3.00

Select another date:

Mon, Feb 5 2018

BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH

* SAYS ‍RECENTLY HAD A PRE-NDA MEETING WITH FDA; NDA FOR FEXAPOTIDE FOR BPH​ WILL BE SUBMITTED LATER IN 2018 Source text for Eikon: Further company coverage:

BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men

* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN

BRIEF-Nymox Pharmaceutical posts qtrly loss $0.09/shr - SEC filing‍​

* Nymox Pharmaceutical Corp qtrly loss per share $0.09 - SEC filing‍​ Source text: (http://bit.ly/2j7iBgX) Further company coverage:

BRIEF-Nymox Pharmaceutical says ‍European member states accepted MAA​ for fexapotide triflutate

* Says ‍European member states for Nymox's MAA for fexapotide triflutate for treatment of benign prostatic hyperplasia accepted co's MAA​ Source text for Eikon: Further company coverage:

BRIEF-Nymox Pharmaceutical postpones September 16 AUA meeting

* Says September 16 AUA meeting in Amelia Island, Florida postponed due to hurricane disaster in Florida​ Source text for Eikon: Further company coverage:

Select another date: